Ovarian cancer

SEngine Precision Medicine’s PARIS® Test Identifies Novel Drug Combinations for PARP Inhibitor Resistant Ovarian Cancer in Study Published in EBioMedicine

Retrieved on: 
Tuesday, October 20, 2020
Cancer, Clinical medicine, Medicine, RTT, Oncology, PARP inhibitors, Ovarian cancer, Poly (ADP-ribose) polymerase, Olaparib

SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine ,a precision oncology company revolutionizing cancer diagnostics anddrug discoveryby pre-testing drugs on patient-derivedtumor organoids, announced today that the PARIS Test was utilized in a study to identify novel drug combinations to overcome resistance to PARP inhibitors in ovarian cancer.

Key Points: 
  • SEATTLE, Oct. 20, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine ,a precision oncology company revolutionizing cancer diagnostics anddrug discoveryby pre-testing drugs on patient-derivedtumor organoids, announced today that the PARIS Test was utilized in a study to identify novel drug combinations to overcome resistance to PARP inhibitors in ovarian cancer.
  • PARP inhibitors are targeted drugs that have become the standard of care in the treatment of nearly half of ovarian cancers.
  • In this study, researchers used a combination of high throughput siRNA screening and drug testing assays using patient derived tumor cells to identify clinically relevant drug combinations for patients whose tumors were resistant to PARP inhibitors.
  • While we could not help this first patient, this study nominates a novel drug combination for PARP inhibitor resistant ovarian cancer, which could be tested in clinical trials.

PMV Pharma Granted FDA Fast Track Designation of PC14586 for the Treatment of Advanced Cancer Patients that have Tumors with a p53 Y220C Mutation

Retrieved on: 
Tuesday, October 13, 2020
Branches of biology, Clinical medicine, Health, Proteins, Oncology, RTT, Tumor suppressor genes, P53, Programmed cell death, Cancer, ATM serine/threonine kinase, Ovarian cancer

The p53 Y220C mutation is associated with many cancers including but not limited to breast, non-small cell lung cancer, colorectal, pancreatic and ovarian cancers.

Key Points: 
  • The p53 Y220C mutation is associated with many cancers including but not limited to breast, non-small cell lung cancer, colorectal, pancreatic and ovarian cancers.
  • Fast Track designation reflects the recognition by the FDA that PC14586 has the potential to address a significant unmet medical need for advanced cancer patients with a p53 Y220C mutation, said David Mack, Ph.D., President and Chief Executive Officer of PMV Pharma.
  • Phase 2 is an open-label study designed to assess anti-tumor efficacy and safety in patients with solid tumors that have a p53 Y220C mutation.
  • PC14586 is being developed for the treatment of patients with locally advanced or metastatic solid tumors that have a p53 Y220C mutation.

CURE Media Group Announces the 2020 Ovarian Cancer Heroes® Winners

Retrieved on: 
Monday, October 12, 2020
Nursing, Health, Women, Pharmaceutical, Oncology, MEN, Other Science, Research, Hospitals, Consumer, Science, Ovarian cancer, RTT, Cancer, Gynaecology, Ovarian Cancer Research Alliance, Gynaecological cancer, Health, Medical specialties, Wisconsin Ovarian Cancer Alliance, CURE Media Group, GSK

CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches over 1 million patients, has named the winners of its Third Annual Ovarian Cancer Heroes awards program.

Key Points: 
  • CURE Media Group, the industry-leading multimedia platform devoted to cancer updates and research that reaches over 1 million patients, has named the winners of its Third Annual Ovarian Cancer Heroes awards program.
  • The 2020 OC Heroes winners are the following:
    Robin Cohen, B.S.N., RN, OCN, is the CEO and co-founder of the Sandy Rollman Ovarian Cancer Foundation in Wynnewood, Pennsylvania.
  • She has served on the board of directors of the Ovarian Cancer National Alliance, is currently the vice president of the Board of the Ovarian Cancer Research Alliance and serves on the board of the World Ovarian Cancer Coalition.
  • Congratulations to these remarkable heroes who have dedicated their efforts to raising awareness, education and research in ovarian cancer, said Mike Hennessy Jr., president and CEO of MJH Life Sciences, parent company of CURE Media Group.

Global Ovarian Cancer Market and Competitive Landscape Report 2020: Pipeline, Epidemiology, Forecasts, Sales & Competitive Landscape 2016-2024 - ResearchAndMarkets.com

Retrieved on: 
Monday, October 12, 2020
General Health, Pharmaceutical, Health, Oncology, Cancer, Clinical medicine, Medicine, Oncology, RTT, Gynaecology, Antineoplastic drugs, Gynaecological cancer, Ovarian cancer, Chemotherapy

The "Global Ovarian Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Ovarian Cancer Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering.
  • Global Ovarian Cancer Market and Competitive Landscape - 2020, provides comprehensive insights into the Ovarian Cancer pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares.
  • This research analyzes and forecasts the Ovarian Cancer market size and drug sales.
  • Ovarian Cancer pipeline: Find out drugs in clinical trials for the treatment of Ovarian Cancer by development phase 3, phase 2, and phase 1, by pharmacological class and company
    Ovarian Cancer drugs: Identify key drugs marketed and prescribed for Ovarian Cancer in the US, including trade name, molecule name, and company
    Ovarian Cancer market valuations: Find out the market size for Ovarian Cancer drugs in 2019 by countries.

Hanabusa IVF Partnered With Genesis Athens Clinic to Offer a Safe and Proven Ovarian Rejuvenation Therapy

Retrieved on: 
Tuesday, October 6, 2020
Human reproduction, Medical specialties, Anatomy, Gynaecology, Fertility, Reproduction, Menstrual cycle, Primary ovarian insufficiency, In vitro fertilisation, Ovarian reserve, POF, Ovarian cancer

Whereas Hanabusa IVF partnered with the leading pioneers of Ovarian Rejuvenation, Dr. Pantos, and Dr.Sfakianoudis, from the Centre for Human Reproduction, Genesis Athens Clinic, to offer a safe and proven Platelet-Rich Plasma (PRP) protocol.

Key Points: 
  • Whereas Hanabusa IVF partnered with the leading pioneers of Ovarian Rejuvenation, Dr. Pantos, and Dr.Sfakianoudis, from the Centre for Human Reproduction, Genesis Athens Clinic, to offer a safe and proven Platelet-Rich Plasma (PRP) protocol.
  • Hanabusa IVFstrivesto offer unmatched treatment options for women suffering from Premature Ovarian Failure (POF), Premature Ovarian Insufficiency (POI), and women with a low ovarian reserve (low AMH levels) a chance to build their family.
  • "It's exciting to expand and offer alternative treatment options such as ovarian rejuvenation to our patients in Southern California."
  • The doctors at Hanabusa know that one size doesn't fit all andareconstantly growing in the ever-changing field of IVF.

Did You Know That One in Eight Women Are at Risk for Breast Cancer?

Retrieved on: 
Thursday, October 1, 2020
Networks, General Health, Family, Philanthropy, Oncology, Data management, Consumer, Technology, Genetics, Women, Other Philanthropy, Health, RTT, Health, Medicine, Hereditary cancers, Oncology, Breast cancer, Cancer, Ovarian cancer, Preventive healthcare, Cancer syndrome, BRCA mutation, Networks, General Health, Family, Philanthropy, Oncology, Data management, Consumer, Technology, Genetics, Women, Other Philanthropy, Health, RTT, Health, Medicine, Hereditary cancers, Oncology, Breast cancer, Cancer, Ovarian cancer, Preventive healthcare, Cancer syndrome, BRCA mutation, Ancestry and AncestryHealth, Bright Pink

Knowing ones genetic health and family health history are important considerations in understanding possible risk for breast cancer and other health conditions.

Key Points: 
  • Knowing ones genetic health and family health history are important considerations in understanding possible risk for breast cancer and other health conditions.
  • For example, AncestryHealth powered by NGS achieves about 80-90 percent detection of inherited risk for hereditary breast and ovarian cancers.
  • Together, we hope to educate more women about how they can take steps to better understand their genetic health risks.
  • Bright Pinks innovative programs motivate women to prioritize prevention, help women assess their risk for breast and ovarian cancer, equip women with personalized risk-management recommendations, and empower women to manage their health proactively in partnership with a healthcare provider.

TCR² Therapeutics to Present at Jefferies Cell Therapy Virtual Summit

Retrieved on: 
Tuesday, September 29, 2020
RTT, Cancer, Health, Clinical medicine, Mesothelin, Mesothelioma, Ovarian cancer, Non-small-cell lung carcinoma, GL-ONC1

CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the Jefferies Cell Therapy Virtual Summit on Monday, October 5, 2020 at 2:00pm E.T.

Key Points: 
  • CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will participate in a fireside chat at the Jefferies Cell Therapy Virtual Summit on Monday, October 5, 2020 at 2:00pm E.T.
  • using a virtual platform.
  • A live webcast of the presentation will be available on the Investors page of the Companys website at https://investors.tcr2.com .
  • The Companys lead TRuC-T cell product candidate targeting solid tumors, TC-210, is currently being studied in a Phase 1/2 clinical trial to treat patients with mesothelin-positive non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.

VBL Therapeutics to Present at the Chardan 4th Annual Genetic Medicines Conference

Retrieved on: 
Tuesday, September 29, 2020
Health, Articles, RTT, Cancer, Ofranergene obadenovec, Ovarian cancer, Therapy, Biopharmaceutical, Oncology, Targeted therapy

Vascular Biogenics Ltd., operating asVBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications.

Key Points: 
  • Vascular Biogenics Ltd., operating asVBL Therapeutics, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for areas of unmet need in cancer and immune/inflammatory indications.
  • VBLs lead oncology product candidate, ofranergene obadenovec (VB-111), is a first-in-class, targeted anti-cancer gene-therapy agent that is being developed to treat a wide range of solid tumors.
  • Ofranergene obadenovec is currently being studied in a VBL-sponsored Phase 3 potential registration trial for platinum-resistant ovarian cancer.
  • VBL Therapeutics undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

Lumicell Announces Initiation of NIH/NCI Academic-Industry Study of its LUM Imaging System

Retrieved on: 
Tuesday, September 29, 2020
RTT, Health, Clinical medicine, Prostate cancer, Cancer, Breast cancer, Ovarian cancer, Treatment of cancer, Brain metastasis, NeuVax

The study also focuses on collecting data as the first step to investigate the potential long-term impact of the LUM Imaging System in breast cancer treatment.

Key Points: 
  • The study also focuses on collecting data as the first step to investigate the potential long-term impact of the LUM Imaging System in breast cancer treatment.
  • The LUM Imaging System was developed to enable surgeons to see and remove residual cancer in real time during the initial surgery.
  • Data from the Phase C study and the ongoing pivotal study will be used to support an application to the FDA for market approval for the LUM Imaging System.
  • Lumicell is investigating the LUM Imaging System in patients undergoing surgery for breast cancer, prostate cancer, colorectal, esophageal, ovarian, peritoneal and brain cancers.

Predictive Oncology Secures License for an Additional 71 Unique Ovarian Cancer Cell Lines from Ximbio, Cancer Research UK’s Premier Reagents Distributor

Retrieved on: 
Tuesday, September 22, 2020
Gynaecology, RTT, Anatomy, Branches of biology, Gynaecological cancer, Health, Ovarian tumor, Proteome, Ovarian cancer, Ovary, Cancer

These cell lines were licensed from the English company, Ximbio, the worlds largest non-profit dedicated to life science reagents of all kinds.

Key Points: 
  • These cell lines were licensed from the English company, Ximbio, the worlds largest non-profit dedicated to life science reagents of all kinds.
  • Adding these 71 cell lines to our existing 25 cell lines (11 of the first 25 are representative of about 95% of ovarian tumors) adds a powerful new resource for researchers.
  • The media used to grow the novel and unique ovarian cancer cell lines, licensed by Predictive Oncology and its partner, GLG Pharma, is able to retain 95%+ of the cells DNA and RNA as well as crucial proteomic signatures.
  • In additional, these cell lines, generally speaking, are not representative of the patients unique ovarian cancer.